Authors

Latest:

Dr Masarova on the Investigation of Ropeginterferon Alfa in Essential Thrombocythemia

Lucia Masarova, MD, discusses the investigation of ropeginterferon alfa in adult patients with essential thrombocythemia, highlighting the unmet needs that investigators aim to address with this investigation.

Sunil Iyer, MD

Latest:

Dr Iyer on the Mechanism of Action of Imetelstat in Lower-Risk MDS

Sunil Iyer, MD, discusses the mechanism of action of imetelstat in patients with lower-risk myelodysplastic syndrome with anemia.

Antonio Cigliola, MD

Latest:

Dr Cigliola on Potential Implications of the SURE-01 and SURE-02 Trials in MIBC

Antonio Cigliola, MD, discusses potential clinical implications of data from the phase 2 SURE-01 and SURE-02 trials in MIBC.

Christina S. Baik, MD, MPH

Latest:

Dr Baik on the Clinical Utility of Zongertinib in Previously Treated HER2-Mutant NSCLC

Christina S. Baik, MD, MPH, discusses the clinical utility of zongertinib in previously treated non–small cell lung cancer harboring HER2 TKD mutations.

Benjamin Creelan, MD

Latest:

Dr Creelan on the Promise of Cemiplimab in Squamous NSCLC

Ben Creelan, MD, discusses survival outcomes with cemiplimab in patients with squamous non–small cell lung cancer.

Kari Hacker, MD, PhD

Latest:

Dr Hacker on the Proportion of HER2-Expressing Tumors in Endometrial Cancer

Kari Hacker, MD, PhD, discusses the proportion of HER2-expressing endometrial cancers eligible for HER2-targeted antibody-drug conjugate treatment.

Christopher S. Lathan, MD, MS, MPH

Latest:

Dr Lathan on Community-based Cancer Evaluation Services in Underserved Patient Groups

Christopher Lathan, MD, MS, MPH, discusses socioeconomical and clinical findings from a clinical outreach program incorporating cancer diagnostic services and patient navigation for patients from traditionally underserved populations.

Whitfield B. Growdon, MD

Latest:

Dr Growdon on the Withdrawal of Later-Line Indication For Olaparib in BRCA-Mutated Ovarian Cancer

Whitfield B. Growdon, MD, expands on the FDA’s decision to withdraw the later-line indication of olaparib for patients with BRCA-mutated ovarian cancer.

Jobelle Baldonado, MD

Latest:

Dr Baldonado on the Evolution of Targeted Therapy in NSCLC

Jobelle Baldonado, MD, discusses the evolution of personalized approaches to treatment in non–small cell lung cancer.

Hao G. Nguyen MD, PhD

Latest:

Dr. Nguyen on the Efficacy of IS-002 for Robotic Prostatectomy in Prostate Cancer

Hao G. Nguyen MD, PhD, discusses the efficacy and safety of IS-002, a prostate-specific membrane antigen–targeting fluorophore, for image-guided surgery in patients with prostate cancer undergoing robotic prostatectomy.

Vivek K. Narayan, MD, MS

Latest:

Dr Narayan on the Evolving Treatment Paradigm in Metastatic Urothelial Carcinoma

Vivek K. Narayan, MD, MS, discusses potential avenues for treatment considerations in patients with metastatic urothelial carcinoma.

Jan Philipp Bewersdorf, MD

Latest:

Dr Bewersdorf on Ruxolitinib Plus Abemaciclib in Myelofibrosis

Jan Bewersdorf, MD, discusses the design of an ongoing phase 1 trial investigating ruxolitinib plus abemaciclib in patients with primary or secondary myelofibrosis.

Brandon S. Sheffield, MD

Latest:

Dr. Sheffield on the Economic Cost of Delaying of Treatment in NSCLC

Brandon S. Sheffield, MD, discusses the economic cost of delaying treatment while conducting biomarker testing in non–small cell lung cancer.

Lajos Pusztai, MD, PhD, Yale Cancer Center

Latest:

HR+ Breast Cancer: Role of RxPONDER Data in Clinical Practice

Lajos Pusztai, MD, PhD, and Priyanka Sharma, MD, share closing thoughts on additional data they hope to see from the RxPONDER trial, and using these data in clinical practice for the treatment of HR+ early breast cancer.

Hana Safah, MD

Latest:

Supportive Care and Medication Access in GvHD

Hana Safah, MD, and Corey Cutler, MD, MPH, conclude with clinical insights on addressing medication access and the supportive care needs of patients with GvHD.

Jen-Jane Liu, MD

Latest:

Dr Liu on the Use of PSMA PET to Inform Lymph Node Dissection in Prostate Cancer

Jen-Jane Liu, MD, discusses how prostate-specific membrane antigen PET imaging may help inform lymph node dissection in the localized disease setting for patients with prostate cancer.

Karamjeet Singh Sandhu, MD

Latest:

Dr Sandhu on a Pooled Analysis of the FELIX Trial in Relapsed/Refractory B-ALL

Karamjeet Singh Sandhu, MD, discusses outcomes from a pooled analysis of the FELIX study in relapsed/refractory B-cell acute lymphoblastic leukemia.

Anwaar Saeed, MD

Latest:

Future Directions in the Management of Hepatocellular Carcinoma

To close, Dr. Saeed and Dr. Singal share their excitement for the future landscape, emerging agents and treatment strategies for patients with HCC.

Jordan B. Milner, MD

Latest:

Dr. Milner on Hematopoietic Stem Cell Transplant in Aplastic Anemia

Jordan B. Milner, MD, discusses findings from a study evaluating the use of hematopoietic stem cell transplant up front or as salvage therapy after unsuccessful immunosuppressive therapy in pediatric patients with severe aplastic anemia.

A. Oliver Sartor, MD, Tulane Cancer Center

Latest:

Rapid Readouts: Results from the Phase 3 VISION Study

A. Oliver Sartor, MD, presents data from the American Society of Clinical Oncology 2021 annual meeting from the VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.